PACB is currently covered by 3 analysts with average potential upside of $2.55 (27.16%) backed by 32 price targets and 46 ratings. Documented since 27-Jul-2012. Analyst's average stock valuation to be materialised ratio is 78.47% with an average time for price targets to be met of 358.5 days.
Most recent stock forecast was given by KYLE MIKSON from CANACCORD on 16-Nov-2022.
Highest price target for PACB is 35, Lowest price target is 6, average price target is 20.5.
Currently, out of the existing stock ratings of PACB - 7 which are a Hold (58.33%), 5 which are a Buy (41.67%)
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average time for PT to be met
Performance score
Buy
14
$4.24 (43.44%)
40
4 months 15 days ago
5/10 (50%)
$10.14 (58.53%)
64
Hold
6
$-3.76 (-38.52%)
6
7 months 12 days ago
2/4 (50%)
$1.04 (7.22%)
7
Hold
30
$20.24 (207.38%)
30
1 years 5 months 16 days ago
4/4 (100%)
$0.87 (12.44%)
109
Hold
52
$42.24 (432.79%)
20
2 years 1 months 20 days ago
5/6 (83.33%)
$-1.89 (4.53%)
565
Buy
52
$42.24 (432.79%)
12
2 years 1 months 20 days ago
7/8 (87.5%)
$0.68 (12.65%)
393
What is PACB(Pacific Biosciences of California, Inc) average time for price targets to be met?
Which analyst has the current highest performing score on PACB(Pacific Biosciences of California, Inc) with a proven track record?
